Genexine Inc (095700) — Cash Flow-to-Debt Ratio
Genexine Inc (095700) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of ₩-2.97 Billion could theoretically repay 0% of its total liabilities (₩106.21 Billion) in one year. See free cash flow generation of Genexine Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Genexine Inc Cash Flow-to-Debt Ratio (2009–2024)
Historical debt coverage capacity for Genexine Inc across 14 annual periods. Also explore how fast is Genexine Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Genexine Inc (2009–2024)
Year-by-year debt coverage analysis for Genexine Inc. For market capitalisation and broader financial context, see 095700 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | ₩-1.65 Billion | ₩83.36 Billion | ▲ +95.9% |
| 2023 | -0.48x | ₩-38.05 Billion | ₩79.68 Billion | ▼ -35.1% |
| 2022 | -0.35x | ₩-39.80 Billion | ₩112.63 Billion | ▼ -230.3% |
| 2021 | -0.11x | ₩-12.75 Billion | ₩119.12 Billion | ▲ +71.1% |
| 2020 | -0.37x | ₩-22.69 Billion | ₩61.30 Billion | ▲ +45.4% |
| 2019 | -0.68x | ₩-41.57 Billion | ₩61.27 Billion | ▼ -83.7% |
| 2018 | -0.37x | ₩-20.05 Billion | ₩54.30 Billion | ▲ +62.1% |
| 2017 | -0.97x | ₩-26.10 Billion | ₩26.83 Billion | ▼ -96.5% |
| 2016 | -0.50x | ₩-14.10 Billion | ₩28.47 Billion | ▼ -392.5% |
| 2015 | -0.10x | ₩-1.64 Billion | ₩16.33 Billion | ▼ -205.8% |
| 2012 | 0.10x | ₩1.67 Billion | ₩17.55 Billion | ▲ +141.4% |
| 2011 | -0.23x | ₩-3.48 Billion | ₩15.14 Billion | ▲ +44.1% |
| 2010 | -0.41x | ₩-4.62 Billion | ₩11.24 Billion | ▼ -5091.0% |
| 2009 | 0.01x | ₩35.23 Million | ₩4.28 Billion | — |